Marinus Pharmaceuticals (NASDAQ:MRNS) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a report published on Tuesday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Marinus Pharmaceuticals Trading Down 0.2%

Shares of NASDAQ:MRNS opened at $0.55 on Tuesday. The stock has a fifty day simple moving average of $0.55 and a two-hundred day simple moving average of $0.47. The stock has a market capitalization of $30.32 million, a price-to-earnings ratio of -0.22 and a beta of 1.03. Marinus Pharmaceuticals has a 12-month low of $0.22 and a 12-month high of $1.97.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in MRNS. JPMorgan Chase & Co. raised its stake in Marinus Pharmaceuticals by 1,968.5% during the third quarter. JPMorgan Chase & Co. now owns 133,191 shares of the biopharmaceutical company’s stock valued at $234,000 after buying an additional 126,752 shares during the last quarter. Deltec Asset Management LLC purchased a new position in Marinus Pharmaceuticals during the fourth quarter valued at $107,000. Virtu Financial LLC purchased a new position in Marinus Pharmaceuticals during the fourth quarter valued at $36,000. XTX Topco Ltd raised its stake in Marinus Pharmaceuticals by 1,564.7% during the fourth quarter. XTX Topco Ltd now owns 219,819 shares of the biopharmaceutical company’s stock valued at $118,000 after buying an additional 206,614 shares during the last quarter. Finally, GABELLI & Co INVESTMENT ADVISERS INC. purchased a new position in Marinus Pharmaceuticals during the fourth quarter valued at $54,000. Hedge funds and other institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.